Evidence vs influencers: The FDA vote putting patients in danger

The FDA's Pharmacy Compounding Advisory Committee recently faced a pivotal decision that blurred the line between medical evidence and influencer trends. In a narrow vote, the committee suggested allowing compounding pharmacies to offer certain peptides, despite limited scientific backing. This move risks prioritizing popular trends over patient safety and could undermine the FDA's role in distinguishing between effective medical treatments and unproven practices. This decision underscores a broader issue about how regulatory bodies balance innovation with rigorous scientific validation.